SIDP
Business Meeting and Lecture Series
November 6th, 2021
Program Book
## Agenda

<table>
<thead>
<tr>
<th>Time (Eastern)</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 10:00 – 10:45 am     | President’s Welcome Business Meeting Strategic Planning Treasury Report | Susan L. Davis, PharmD, FIDP  
Clinical Professor and Interim Associate Dean of Pharmacy  
Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences |
| 10:45 – 11:30 am     | Keynote Presentation  
The Urgent Need for Trustworthy Scientific Communication in Infectious Diseases | Peter Hotez, MD, PhD  
Dean, National School of Tropical Medicine, Professor of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine;  
Co-director, Texas Children’s Center for Vaccine Development |
| 11:30 – 11:40 am     | Break                                                                 |                                                                                                                                         |
| 11:40 – 12:40 pm     | Research Platform Presentations                                       |                                                                                                                                         |
|                      | Research Platform Presentation #1  
Antipseudomonal versus Narrow-spectrum Agents for the Treatment of Community-onset Intra-abdominal Infections |                                                                                                                                         |
|                      | Research Platform Presentation #2  
Pharmacogenomic Testing Provides Insight and Enhances Medication Management in People Living with HIV |                                                                                                                                         |
|                      | Research Platform Presentation #3  
Immediate Hypersensitivity to Fluoroquinolones: A Cohort Assessing Cross-Reactivity |                                                                                                                                         |
|                      | Research Platform Presentation #4  
Current State of Infectious Diseases Pharmacist OPAT/COpAT Practice in the United States |                                                                                                                                         |
| 12:40 – 1:25 pm      | Lunch and Exhibitor Hall Break                                        |                                                                                                                                         |
| 1:25 – 2:05 pm       | CE Presentation #1  
Spiraling Empiricism vs. Science: The Stewardship Dilemma of Breakthrough Fungal Infections | Russell Lewis, PharmD, FCCP  
Associate Professor of Medical and Surgical Services, University of Bologna, Infectious Diseases Unit, IRCCS  
St. Orsola-Malpighi Univ Hosp. Bologna, Italy |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 2:05 – 2:45 pm | **CE Presentation #2**  
Critical Updates in the Treatment of HIV and STIs | Rodrigo Burgos, Pharm D, MPH  
Clinical Assistant Professor, Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy |
| 2:45 – 2:55 pm | **Break**                                                            |                                                                            |
| 2:55 – 3:35 pm | **CE Presentation #3**  
Blood Boiling Debate: Can I Really Use Ceftriaxone for MSSA Bacteremia? | Kira Beaulac, PharmD, BCIDP  
Antimicrobial Stewardship Pharmacist, Emerson Hospital  
Jamie Wagner, PharmD, BCPS  
Clinical Associate Professor of Pharmacy Practice, University of Mississippi School of Pharmacy |
| 3:35 – 4:20 pm | **Awards**  
New Fellows  
Installation of Incoming Board Members | Susan L. Davis, PharmD, FIDP  
Clinical Professor and Interim Associate Dean of Pharmacy, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences |
| 4:20 – 4:30 pm | **Incoming President’s Remarks**                                     | Scott Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP  
Antimicrobial Stewardship Coordinator, Nebraska Medicine  
Clinical Associate Professor, University of Nebraska Medical Center, College of Pharmacy |
CE CREDIT INSTRUCTIONS

1. To receive CE credit (ACPE & BCIDP) for the activities at this conference, you must complete the post-tests and evaluations online no later than Friday, December 10, 2021.
3. Click on the blue Evaluation button which is listed with the SIDP Annual Meeting activity.
4. Login to the ProCE CE Center. Note: You will need to sign up for a new account if you have not previously used the ProCE CE Center.
5. Click the Enroll Now button then enter the Attendance Codes for all of the CE sessions you attended. NOTE: Each session has a unique attendance code.
6. Take the post-tests, complete the evaluations, and claim CE credit. NOTE: Claim CE credit only for the sessions you attended.
7. If you need assistance or have questions, please contact ProCE at 888-213-4061 or via email at info@proce.com.

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Session Title</th>
<th>CPE Hours</th>
<th>ACPE UAN</th>
<th>Attendance Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40 AM - 12:40 PM ET</td>
<td>Research Platform Presentations</td>
<td>1.0</td>
<td>0221-9999-21-273-L01-P</td>
<td></td>
</tr>
<tr>
<td>1:25 - 2:05 PM ET</td>
<td>Spiraling Empiricism vs. Science: The Stewardship Dilemma of Breakthrough Fungal Infections</td>
<td>0.75</td>
<td>0221-9999-21-274-L01-P</td>
<td></td>
</tr>
<tr>
<td>2:05 - 2:45 PM ET</td>
<td>Critical Updates in the Treatment of HIV and STIs</td>
<td>0.75</td>
<td>0221-9999-21-275-L01-P</td>
<td></td>
</tr>
<tr>
<td>2:55 - 3:35 PM ET</td>
<td>Blood Boiling Debate: Can I Really Use Ceftriaxone for MSSA Bacteremia?</td>
<td>0.75</td>
<td>0221-9999-21-276-L01-P</td>
<td></td>
</tr>
</tbody>
</table>

Note: BCIDP credit will be available for all of the sessions listed above except the Research Platform Presentations. It is ProCE policy that CE requirements (i.e., post-test, if applicable for the specific CE activity, and evaluation) be completed within 30 days of the live activity date to ensure an on-time submission to your CPE Monitor account.

ACPE & BCIDP ACCREDITATION

The Continuing Pharmacy Education (CPE) activities are jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists (SIDP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of Continuing Pharmacy Education. The release date for these four activities is November 6, 2021. A maximum of 3.25 contact hours may be earned for participation in the four CE activities. Participants must complete an online post-test and evaluation for each session they attend to receive pharmacy CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. All post-tests and evaluations must be completed no later than December 10, 2021. No partial credit will be given for any individual session. The Target Audience for these CPE activities is pharmacists.

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of each of the post-tests and online evaluations. Each of the post-tests must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 11/6/2021 for these activities and is available for one year from this date. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education

Faculty Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Escape Room

2021 SIDP Business Meeting Escape Room Details and Instructions:

We are excited to host a virtual “Infectious Diseases (ID) Escape Room” for the 2021 SIDP Business Meeting! The Escape Room will feature engaging activities that registered SIDP Members can complete as individuals. Some of these activities will require information available through discussion with our Business Meeting sponsors. Fun prizes will be offered for three individuals [one trainee member, one early career member (within 10 years of terminal training), one member with >10 years of practice] who complete the Escape Room the fastest!

A customized, password protected Google Forms link will be available in the chat feature to Registered Attendees with explicit instructions related to the ID Escape Room activities. The ID Escape Room will open on November 6th 12:40 p ET and close at 1:25 p ET, which will be announced to the audience. Attendees will have unlimited chances to submit and unlock the puzzle in order to unlock the subsequent activity during this timeframe only. Attendees must unlock each room to proceed through the activity.

The first individuals in each category who successfully unlock each activity the fastest will be awarded prize packages. The SIDP Fundraising Committee will monitor Google Form submission times, which can document the time an individual submits the form correctly, in order to identify the winning individuals. These winners will be announced during the Business Meeting and in the next SIDP newsletter!
Navigate to our Virtual Booth

Connect with a representative and learn about the portfolio of Astellas products
LEADING THE SCIENCE OF PROTECTION

Cidara is developing long-acting therapeutics for patients facing serious diseases

Cidara.com
A VICIOUS CYCLE WITH SIGNIFICANT BURDEN

WHAT COULD BE THE CONSEQUENCES OF RECURRENT C. DIFFICILE INFECTION?

Learn why it requires aggressive action

THE CDC ACKNOWLEDGES C. DIFFICILE INFECTION AS A MAJOR AND URGENT THREAT!

IT RECURS IN UP TO 35% OF CASES WITHIN 8 WEEKS AFTER INITIAL DIAGNOSIS.1

THE CONSEQUENCES OF RECURRENCE ARE SIGNIFICANT, POTENTIALLY DEADLY?

Now is the time to learn how Ferring is shedding light on the link between disease and disruptions in the gut microbiome, exploring the potential for repopulating its diversity and restoring hope to patients.

Antimicrobial resistance threatens everyone. All of us need to be resistance fighters.

Learn more about drug resistant infections by listening to the new podcast series: SUPERBUGS AND YOU, True Stories from Scientists and Patients around the World.

This podcast series will address this global crisis through conversations with patients, clinicians, and researchers to discover how superbugs are affecting people and healthcare systems globally.

Learn, act, and be inspired.

Episode 1: A global problem close to home
In this episode we discuss the global impact of multidrug-resistant gram-negative bacterial infections.

Episode 2: Stalking the silent killer
Learn about sepsis and the increased challenge of an infection that is caused by a drug resistant microorganism.

Episode 3: Resistance that spreads through the air
Learn about the global issue of multi-drug resistant tuberculosis or TB.

Episode 4: A future foretold
Learn about the complexity of treating COVID-19 patients, including the challenge of co-infections with drug resistance bacteria.

Access podcasts at antimicrobialresistancefighters.org
Also available on Apple Podcasts, Spotify, and Google Podcasts.
Introducing an interactive, customizable, Infectious Diseases (ID) resource app

ILÚM Inform

Educate staff on appropriate antimicrobial use

Incorporate your local antibiogram and local data into the pathogen and antimicrobial agent libraries

Contact your key clinicians and hospital units directly from the app

Communicate timely guideline updates, formulary changes, and more!

Contact us for a demo at sales@idctelemed.com
Now Offering:
Web, Mobile, & EHR Access
Custom Apps for AMS Guidelines
Vancomycin AUC_{24} Calculator
Hospital & Health System Licenses

From our team to yours:

Thank you for your work!

learn more at
www.sanfordguide.com/sidp
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based therapies to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential. Our mission is to provide an effective long-term solution for the global coronavirus challenge.

We aim to address COVID-19 and future potential coronavirus outbreaks by building a portfolio of antibodies with broadly neutralizing activity against multiple members of the coronavirus family. Our lead product candidate, ADG20, is designed to be a potent, long-acting, and broadly neutralizing antibody and is in pivotal trials for both the treatment and prevention of COVID-19.

https://adagiotx.com

Yes, you can have your cake and eat it too

Asolva MEDICI®
End-to-End Software Solution for Antimicrobial Stewardship

- Satisfies CDC Core Elements for Hospital ASP
- Supports Multi-Disciplinary ASP Team
- Most Affordable Software Solution on the Market
- Works for Any Hospital Size (CAH friendly)
- Integrates with Any EHR brand
- First to be CDC-Validated for NHSN AU Reporting

Find out how hospitals throughout the US are enjoying their cake. www.asolva.com
The next evolution in bloodstream pathogen diagnostics

Species identification direct from whole blood
Shorter time to targeted therapy

Stop waiting days for results.
t2biosystems.com
Thank You to Our Sponsors

We encourage you to visit each sponsor in our Virtual Exhibit Hall!

Virtual Exhibit Hall
Thank You to Our Sponsors

We encourage you to visit each sponsor in our Virtual Exhibit Hall!

Virtual Exhibit Hall

Asolva

BIOFIRE

T2 Biosystems

adagio

Gilead

melinta therapeutics

Abbvie